Oryzon Genomics, a CataloniaBio & HealthTech member, has carried out a €20-million capital increase through private international investors, after presenting promising clinical results at several congresses.

The company, which specialises in innovative epigenetic therapies, has recently finished recruiting patients for its Phase IIa clinical trials to assess the safety, tolerability and efficacy of vafidemstat (ORY-2001) in various psychiatric and neurodegenerative diseases. 

Vafidemstat is an oral molecule that curbs cognitive degeneration, memory loss and neuroinflammation, as well as showing neuroprotective effects. In preclinical trials, Vafidemstat restored cognitive deterioration and eliminated aggressiveness in SAMP8 mice, a model with advanced ageing and Alzheimer.

In the first half of 2019, Oryzon invested €4.9 million in R&D and saw revenue of €4.4 million, up 18.9% from 2018. The biotechnology company’s net result for this phase of development is a loss of €1.8 million. 

The company will present at several reputed international conferences in September.

Photo: Carlos Buesa, co-founder and CEO - © Oryzon